SuperCom Ltd. (NASDAQ: SPCB), a global provider of secure solutions for the e-Government, IoT, and cybersecurity sectors, is announcing that it has secured new electronic monitoring contracts with multiple Sheriff agencies across West Virginia. These contracts leverage SuperCom’s innovative PureOne suite to provide robust monitoring solutions in rural areas. According to the announcement, the contracts…
PaxMedica (OTC: PXMD), a biopharmaceutical company specializing in neurological disorder treatments, is preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration for suramin to treat Human African Trypanosomiasis (“HAT”). “In April 2024, PaxMedica underscored its commitment to global health by responding to an urgent request from Malawi for an…
Correlate (OTCQB: CIPI) is positioned as a combination of unprecedented levels of government incentives and growing private sector investment funding are pushing a noteworthy shift in energy trends. The momentum shows decentralized electrical energy generation gaining an increasing following according to an MSE Investments report praising the visionary qualities of Correlate Energy. “The distributed energy…
SenesTech’s (NASDAQ: SNES) flagship product, Evolve(TM), has repeatedly demonstrated an effective rat control alternative to current market offerings. “The active ingredient in the product has been scientifically proven to reduce rodent fertility, ultimately offering a more proactive approach to addressing the growing rat problem, as opposed to a more reactive approach, as is the case…
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced receipt of blood glucose results from weeks 4 and 8 of its ongoing animal study WEIGHT-A24-1. The study is underway using diabetic, pre-conditioned Zucker rats. The results showed that DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A and B) were…
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, has closed on its previously announced loan restructuring agreement. According to the announcement, the agreement is with the European Investment Bank (“EIB”) and includes…
D-Wave Quantum (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the world’s first commercial supplier of quantum computers, has partnered with NTT DOCOMO Inc., Japan’s largest mobile phone operator, to work on a quantum optimization pilot that resulted in demonstrable mobile network performance improvements. According to the announcement, the project…
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the world’s first commercial supplier of quantum computers, is featured in a NetworkNewsAudio (“NNA”) broadcast. NNA broadcasts are designed to provide additional visibility, recognition and brand awareness to the investment community. According to the broadcast, D-Wave is focused on…
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, has entered into a $2 million Investment Commitment Agreement with RK Stone Miami LLC, an affiliate of the largest shareholder of the company, Mr. Daniel Stone. Under the terms…
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced the sale of the Mullen THREE, Class 3 EV box truck uplift to the facilities operations unit at Princeton University. The Mullen THREE is expected to support the unit’s campus operations as well as contribute to its overall sustainability goals, including reaching zero…
InMed Pharmaceuticals (NASDAQ: INM), a clinical stage company developing a pipeline of pharmaceutical drug candidates to treat several diseases with a high unmet medical need, is at the forefront of developing innovative treatment for age-related macular degeneration (“AMD”), with its flagship product INM-089 showing great promise. “AMD is a prevalent eye condition that primarily affects…
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently hired a Contract Research Organization (“CRO”) for its third human pilot study. “This marks a milestone for the company, notably since it announced its focus solely on glucagon-like peptide 1 (‘GLP-1’) studies for the 2024 calendar year… This randomized, crossover investigation will…
Correlate (OTCQB: CIPI), a tech-enabled development, finance and fulfillment platform for distributed energy solutions across North America, is driving scalability in the microgrid energy distribution market. This follows a new partnership between its subsidiary Distributed Energy Capital (“DEC”) and clean energy development innovator Compass Energy that will establish the United States’ first microgrid utility. “The…
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today released its financial results for the second quarter ended June 30, 2024 (“Q2 2024”). The company also discussed the clinical development progress of Berubicin, its lead program, and…
Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit. The company today published its financial results for the second quarter ended June 30, 2024, and provided a business update. Scinai plans to host a webinar to discuss…
McEwen Mining (NYSE: MUX) (TSX: MUX) is an asset-rich diversified gold and silver producer in the Americas. McEwen CEO Rob McEwen recently spoke at the NYC SME’s 9th Annual Current Trends in Mining Finance Conference, where he emphasized the crucial importance of the mining industry to modern civilization and outlined a strategic approach to improving…
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the signing of a definitive Loan Restructuring Agreement with the European Investment Bank (“EIB”), its lender. The agreement also included an amendment and restatement to the Finance…
SOBRsafe (NASDAQ: SOBR), a provider of next-generation, transdermal alcohol-detection solutions, is reporting on its NASDAQ listing, financial positioning and sales progress, noting that the NASDAQ Hearings Panel granted the company an exception period continuing the listing of its common stock on the NASDAQ exchange; the company has until Oct. 23, 2024, to regain compliance with…
Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting preclinical data regarding its lead compound, buntanetap. According to the announcement, the results show the synergistic effect of buntanetap when combined with the glucagon-like peptide 1 (“GLP-1”) agonist dulaglutide (Trulicity[R])…